A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer
Neoadjuvant chemotherapy aims to improve the outcome of breast cancer patients, but only few would benefit from this treatment. Pathological complete response has been proposed as a surrogate marker for the prediction of long-term clinical benefits; however, 50%–85% patients have an unfavorable path...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-05-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317702899 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839595043973758976 |
|---|---|
| author | Raúl García-Vazquez Erika Ruiz-García Abelardo Meneses García Horacio Astudillo-de la Vega Fernando Lara-Medina Alberto Alvarado-Miranda Héctor Maldonado-Martínez Juan A González-Barrios Alma D Campos-Parra Sergio Rodríguez Cuevas Laurence A Marchat César López-Camarillo |
| author_facet | Raúl García-Vazquez Erika Ruiz-García Abelardo Meneses García Horacio Astudillo-de la Vega Fernando Lara-Medina Alberto Alvarado-Miranda Héctor Maldonado-Martínez Juan A González-Barrios Alma D Campos-Parra Sergio Rodríguez Cuevas Laurence A Marchat César López-Camarillo |
| author_sort | Raúl García-Vazquez |
| collection | DOAJ |
| description | Neoadjuvant chemotherapy aims to improve the outcome of breast cancer patients, but only few would benefit from this treatment. Pathological complete response has been proposed as a surrogate marker for the prediction of long-term clinical benefits; however, 50%–85% patients have an unfavorable pathological complete response to chemotherapy. MicroRNAs are known biomarkers of breast cancer progression; nevertheless, their potential to identify patients with pathological complete response remains poorly understood. Here, we investigated whether a microRNA profile could be associated with pathological complete response in triple-negative breast cancer patients receiving 5-fluorouracil, adriamycin, cyclophosphamide–cisplatin/paclitaxel as a novel neoadjuvant chemotherapy. In the discovery cohort, the expression of 754 microRNAs was examined in tumors from 10 triple-negative breast cancer patients who achieved pathological complete response and 8 without pathological complete response using TaqMan Low-Density Arrays. Unsupervised hierarchical cluster analysis identified 11 microRNAs with significant differences between responder and no-responder patients (fold change ≥ 1.5; p < 0.05). The differential expression of miR-30a, miR-9-3p, miR-770, and miR-143-5p was validated in an independent group of 17 patients with or without pathological complete response. Moreover, Kaplan–Meier analysis showed that expression of these four microRNAs was associated with an increased disease-free survival. Gene ontology classification of predicted microRNA targets indicated that numerous genes are involved in pathways related to chemoresistance, such as vascular endothelial growth factor, focal adhesion kinase, WNT, ERbB, phosphoinositide 3-kinase, and AKT signaling. In summary, we identified a novel microRNA expression signature associated with pathological complete response in breast cancer. We propose that the four validated microRNAs could be used as molecular biomarkers of clinical response in triple-negative breast cancer patients with pathological complete response to neoadjuvant therapy. |
| format | Article |
| id | doaj-art-f70a8a466f5543a9868f5afa6fafadf9 |
| institution | Matheson Library |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-f70a8a466f5543a9868f5afa6fafadf92025-08-02T23:43:26ZengSAGE PublishingTumor Biology1423-03802017-05-013910.1177/1010428317702899A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancerRaúl García-Vazquez0Erika Ruiz-García1Abelardo Meneses García2Horacio Astudillo-de la Vega3Fernando Lara-Medina4Alberto Alvarado-Miranda5Héctor Maldonado-Martínez6Juan A González-Barrios7Alma D Campos-Parra8Sergio Rodríguez Cuevas9Laurence A Marchat10César López-Camarillo11Programas en Biomedicina Molecular y Biotecnología, Instituto Politécnico Nacional, Ciudad de México, MéxicoLaboratorio de Medicina Traslacional, Instituto Nacional de Cancerología, Ciudad de México, MéxicoLaboratorio de Medicina Traslacional, Instituto Nacional de Cancerología, Ciudad de México, MéxicoLaboratorio de Investigación Traslacional en Cáncer y Terapia Celular, Hospital de Oncología, Centro Médico Siglo XXI, Ciudad de México, MéxicoUnidad de Cáncer de Mama, Instituto Nacional de Cancerología, Ciudad de México, MéxicoUnidad de Cáncer de Mama, Instituto Nacional de Cancerología, Ciudad de México, MéxicoDepartamento de Patología, Instituto Nacional de Cancerología, Ciudad de México, MéxicoLaboratorio de Medicina Genómica, Hospital Regional 1 de Octubre ISSSTE, Ciudad de México, MéxicoLaboratorio de Genómica, Instituto Nacional de Cancerología, Ciudad de México, MéxicoInstituto de Enfermedades de la Mama, FUCAM, Ciudad de México, MéxicoProgramas en Biomedicina Molecular y Biotecnología, Instituto Politécnico Nacional, Ciudad de México, MéxicoPosgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, Ciudad de México, MéxicoNeoadjuvant chemotherapy aims to improve the outcome of breast cancer patients, but only few would benefit from this treatment. Pathological complete response has been proposed as a surrogate marker for the prediction of long-term clinical benefits; however, 50%–85% patients have an unfavorable pathological complete response to chemotherapy. MicroRNAs are known biomarkers of breast cancer progression; nevertheless, their potential to identify patients with pathological complete response remains poorly understood. Here, we investigated whether a microRNA profile could be associated with pathological complete response in triple-negative breast cancer patients receiving 5-fluorouracil, adriamycin, cyclophosphamide–cisplatin/paclitaxel as a novel neoadjuvant chemotherapy. In the discovery cohort, the expression of 754 microRNAs was examined in tumors from 10 triple-negative breast cancer patients who achieved pathological complete response and 8 without pathological complete response using TaqMan Low-Density Arrays. Unsupervised hierarchical cluster analysis identified 11 microRNAs with significant differences between responder and no-responder patients (fold change ≥ 1.5; p < 0.05). The differential expression of miR-30a, miR-9-3p, miR-770, and miR-143-5p was validated in an independent group of 17 patients with or without pathological complete response. Moreover, Kaplan–Meier analysis showed that expression of these four microRNAs was associated with an increased disease-free survival. Gene ontology classification of predicted microRNA targets indicated that numerous genes are involved in pathways related to chemoresistance, such as vascular endothelial growth factor, focal adhesion kinase, WNT, ERbB, phosphoinositide 3-kinase, and AKT signaling. In summary, we identified a novel microRNA expression signature associated with pathological complete response in breast cancer. We propose that the four validated microRNAs could be used as molecular biomarkers of clinical response in triple-negative breast cancer patients with pathological complete response to neoadjuvant therapy.https://doi.org/10.1177/1010428317702899 |
| spellingShingle | Raúl García-Vazquez Erika Ruiz-García Abelardo Meneses García Horacio Astudillo-de la Vega Fernando Lara-Medina Alberto Alvarado-Miranda Héctor Maldonado-Martínez Juan A González-Barrios Alma D Campos-Parra Sergio Rodríguez Cuevas Laurence A Marchat César López-Camarillo A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer Tumor Biology |
| title | A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer |
| title_full | A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer |
| title_fullStr | A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer |
| title_full_unstemmed | A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer |
| title_short | A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer |
| title_sort | microrna signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple negative breast cancer |
| url | https://doi.org/10.1177/1010428317702899 |
| work_keys_str_mv | AT raulgarciavazquez amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT erikaruizgarcia amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT abelardomenesesgarcia amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT horacioastudillodelavega amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT fernandolaramedina amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT albertoalvaradomiranda amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT hectormaldonadomartinez amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT juanagonzalezbarrios amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT almadcamposparra amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT sergiorodriguezcuevas amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT laurenceamarchat amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT cesarlopezcamarillo amicrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT raulgarciavazquez micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT erikaruizgarcia micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT abelardomenesesgarcia micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT horacioastudillodelavega micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT fernandolaramedina micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT albertoalvaradomiranda micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT hectormaldonadomartinez micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT juanagonzalezbarrios micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT almadcamposparra micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT sergiorodriguezcuevas micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT laurenceamarchat micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer AT cesarlopezcamarillo micrornasignatureassociatedwithpathologicalcompleteresponsetonovelneoadjuvanttherapyregimenintriplenegativebreastcancer |